There has been a longstanding need to develop improved methods for the rapid detection of
response to anti-cancer therapies. Circulating tumor DNA based liquid biopsies allow for …

Purpose: Noninvasive drug biomarkers for the early assessment of tumor response can
enable adaptive therapeutic decision-making and proof-of-concept studies for …

e23060 Background: The presence of a targetable driver mutation in nearly 50% non-small
cell lung cancer (NSCLC) patients has enabled tailoring therapy regimens to improve …

Background Liquid biopsy has evolved from being a promising line to becoming a validated
approach for biomarker testing. However, its utility for individualization of therapy has been …

With the advent of precision oncology, there is an urgent need to develop improved methods
for rapidly detecting responses to targeted therapies. Here, we have developed an …

Objectives: During targeted therapy, tumor heterogeneity can drive the evolution of multiple
tumor subclones harboring unique resistance mechanisms. Sequential profiling of plasma …

Objectives Genomic profiling using plasma cell-free DNA (cfDNA) represents a non-invasive
alternative to tumor re-biopsy, which is challenging in clinical practice. The feasibility of …

Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced
non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to …

Background The aim of this study was to evaluate the potential of liquid biopsy for prediction
of the efficacy of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) …

Purpose: Drug tolerance has emerged as one of the major mechanisms driving resistance to
targeted therapies (TT), but a comprehensive understanding of the dynamics and molecular …